Top investors say Panbela Therapeutics Inc. (PBLA) ticks everything they need

Panbela Therapeutics Inc. (NASDAQ: PBLA) stock fell -8.39% on Tuesday to $2.51 against a previous-day closing price of $2.74. With 0.99 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.34 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.0538 whereas the lowest price it dropped to was $2.5100. The 52-week range on PBLA shows that it touched its highest point at $96.00 and its lowest point at $2.08 during that stretch. It currently has a 1-year price target of $380.00. Beta for the stock currently stands at 1.18.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PBLA was down-trending over the past week, with a drop of -23.48%, but this was down by -20.57% over a month. Three-month performance dropped to -66.15% while six-month performance fell -95.25%. The stock lost -96.04% in the past year, while it has lost -14.39% so far this year. A look at the trailing 12-month EPS for PBLA yields -90.29 with Next year EPS estimates of -16.60. For the next quarter, that number is -3.60. This implies an EPS growth rate of -40.40% for this year and 72.70% for next year.

Float and Shares Shorts:

At present, 1.18 million PBLA shares are outstanding with a float of 1.09 million shares on hand for trading. On Dec 29, 2022, short shares totaled 32040.0, which was 4.04% higher than short shares on Nov 29, 2022. In addition to Dr. Jennifer K. Simpson C.R.N.P., CRNP, M.S.N., Ph.D. as the firm’s CEO, Pres & Director, Ms. Susan Horvath serves as its VP of Fin., CFO, Sec. & Treasurer.

Institutional Ownership:

Through their ownership of 6.31% of PBLA’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 9.23% of PBLA, in contrast to 0.14% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in PBLA with 6.86% of the stake, Armistice Capital LLC holds 2,176,809 shares worth 2,176,809. A second-largest stockholder of PBLA, The Vanguard Group, Inc., holds 222,303 shares, controlling over 0.70% of the firm’s shares. UBS Securities LLC is the third largest shareholder in PBLA, holding 190,493 shares or 0.60% stake.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Sep 29, 2022, PBLA reported revenue of $0.00 and operating income of -$21.29M. The EBITDA in the recently reported quarter was -$22.13M and diluted EPS was -$60.40.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PBLA since 1 analysts follow the stock currently. There are 0 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With PBLA analysts setting a high price target of $240.00 and a low target of $240.00, the average target price over the next 12 months is $240.00. Based on these targets, PBLA could surge 9461.75% to reach the target high and rise by 9461.75% to reach the target low. Reaching the average price target will result in a growth of 9461.75% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. PBLA will report FY 2022 earnings on 03/22/2024. Analysts have provided yearly estimates in a range of -$60.80 being high and -$60.80 being low. For PBLA, this leads to a yearly average estimate of -$60.80. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Panbela Therapeutics Inc. surprised analysts by $0.40 when it reported -$8.40 EPS against a consensus estimate of -$8.80. The surprise factor in the prior quarter was -$50.00. Based on analyst estimates, the high estimate for the next quarter is -$3.60 and the low estimate is -$3.60. The average estimate for the next quarter is thus -$3.60.

Summary of Insider Activity:

Insiders traded PBLA stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 3 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 398,000 while 0 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *